Efficacy of hemostatic powders as monotherapy or rescue therapy in gastrointestinal bleeding related to neoplastic or non-neoplastic lesions

Omero Alessandro Paoluzi, Carla Cardamone, Antonio Aucello, Benedetto Neri, Enrico Grasso, Mario Giannelli, Laura Di Iorio, Giovanni Monteleone, Giovanna Del Vecchio Blanco
2021 Scandinavian Journal of Gastroenterology  
Hemostatic powder (HP) in gastrointestinal bleeding (GIB) is mainly used as rescue therapy after failure of conventional hemostatic procedures (CHP). To define the best field of application and the efficacy of HP as first choice monotherapy or rescue therapy. We compared the efficacy of HP monotherapy, HP rescue therapy, and CHP in the management of active GIB due to neoplastic and non-neoplastic lesions. A total of 108 patients, 43 treated with HP as either first choice or rescue therapy and
more » ... with CHP, were included in the study. The most frequent sources of bleeding were peptic ulcer and malignancy. Immediate hemostasis rates were: HP monotherapy = 100% in peptic ulcer and 100% in malignancy; HP rescue therapy = 93.2% in peptic ulcer and 85.7% in malignancy; CHP = 77.9% in peptic ulcer and 41.7 in malignancy. Definitive hemostasis rates were: HP monotherapy = 50% in peptic ulcer and 45.5% in malignancy; HP rescue therapy = 73.3% in peptic ulcer and 85.7% in malignancy; CHP = 69.1% in peptic ulcer and 33.3% in malignancy. No difference was found in terms of additional intervention between the three groups. HP is highly effective as monotherapy and rescue therapy in GIB. GIB related to malignancy may be the best field of application of HP, but confirmatory studies are necessary.
doi:10.1080/00365521.2021.1974088 pmid:34511014 fatcat:ik63ldbkrbhpboovwpujzvk6wu